Stage shift is widely considered a major determinant of the survival benefit conferred by breast cancer screening. However, factors and mechanisms underlying such a prognostic advantage need further clarification. We sought to compare the molecular characteristics of screen detected vs. symptomatic breast cancers and assess whether differences in tumour biology might translate into survival benefit.
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series / Crispo, Anna; Barba, Maddalena; D'Aiuto, Giuseppe; DE LAURENTIIS, Michelino; Grimaldi, Maria; Rinaldo, Massimo; Caolo, Giuseppina; D'Aiuto, Massimiliano; Capasso, Immacolata; Esposito, Emanuela; Amore, Alfonso; Di Bonito, Maurizio; Botti, Gerardo; Montella, Maurizio. - In: BMC CANCER. - ISSN 1471-2407. - 13:(2013), p. 15. [10.1186/1471-2407-13-15]
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series
CRISPO, ANNA;BARBA, MADDALENA;DE LAURENTIIS, MICHELINO;ESPOSITO, EMANUELA;
2013
Abstract
Stage shift is widely considered a major determinant of the survival benefit conferred by breast cancer screening. However, factors and mechanisms underlying such a prognostic advantage need further clarification. We sought to compare the molecular characteristics of screen detected vs. symptomatic breast cancers and assess whether differences in tumour biology might translate into survival benefit.| File | Dimensione | Formato | |
|---|---|---|---|
|
1471-2407-13-15.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
446.83 kB
Formato
Adobe PDF
|
446.83 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
